share_log

Arcutis Biotherapeutics | 8-K: Current report

Arcutis Biotherapeutics | 8-K: Current report

Arcutis Biotherapeutics | 8-K：重大事件
SEC announcement ·  04/10 16:19
Moomoo AI 已提取核心信息
Arcutis Biotherapeutics, Inc., a commercial-stage medical dermatology company, announced the appointment of David Topper as the new Chief Financial Officer (CFO), effective April 10, 2024. Topper succeeds John Smither, who had been serving as the interim CFO. Smither will assist with the transition until his resignation at the end of April. Topper brings over 40 years of experience in finance, investment management, and investment banking to Arcutis. His previous role was CFO at Inmagene Biopharmaceuticals, and he has held significant positions at General Atlantic, Frazier Life Sciences, J.P. Morgan, and Morgan Stanley. Topper's appointment is part of Arcutis' efforts to advance its commercial operations and position itself as a leader in medical dermatology. The company has entered into an employment agreement with Topper, which includes a base salary, performance bonus, and equity awards. The announcement was made via a press release on April 10, 2024, and was also reported in a Form 8-K filing with the SEC.
Arcutis Biotherapeutics, Inc., a commercial-stage medical dermatology company, announced the appointment of David Topper as the new Chief Financial Officer (CFO), effective April 10, 2024. Topper succeeds John Smither, who had been serving as the interim CFO. Smither will assist with the transition until his resignation at the end of April. Topper brings over 40 years of experience in finance, investment management, and investment banking to Arcutis. His previous role was CFO at Inmagene Biopharmaceuticals, and he has held significant positions at General Atlantic, Frazier Life Sciences, J.P. Morgan, and Morgan Stanley. Topper's appointment is part of Arcutis' efforts to advance its commercial operations and position itself as a leader in medical dermatology. The company has entered into an employment agreement with Topper, which includes a base salary, performance bonus, and equity awards. The announcement was made via a press release on April 10, 2024, and was also reported in a Form 8-K filing with the SEC.
处于商业阶段的医学皮肤病公司Arcutis Biotherapeutics, Inc. 宣布任命戴维·托珀为新任首席财务官（CFO），自2024年4月10日起生效。托珀接替了曾担任临时首席财务官的约翰·史密瑟。史密瑟将协助过渡，直到他在4月底辞职。Topper为Arcutis带来了40多年的金融、投资管理和投资银行业务经验。他之前曾在Inmagene Biopharmaceuticals担任首席财务官，并曾在通用大西洋、弗雷泽生命科学、摩根大通和摩根士丹利担任重要职务。Topper的任命是Arcutis努力推进其商业运营并将自己定位为医学皮肤病学领导者的努力的一部分。该公司已与Topper签订了雇佣协议，其中包括基本工资、绩效奖金和股权奖励。该公告是通过2024年4月10日的新闻稿发布的，并已在向美国证券交易委员会提交的8-K表格中进行了报道。
处于商业阶段的医学皮肤病公司Arcutis Biotherapeutics, Inc. 宣布任命戴维·托珀为新任首席财务官（CFO），自2024年4月10日起生效。托珀接替了曾担任临时首席财务官的约翰·史密瑟。史密瑟将协助过渡，直到他在4月底辞职。Topper为Arcutis带来了40多年的金融、投资管理和投资银行业务经验。他之前曾在Inmagene Biopharmaceuticals担任首席财务官，并曾在通用大西洋、弗雷泽生命科学、摩根大通和摩根士丹利担任重要职务。Topper的任命是Arcutis努力推进其商业运营并将自己定位为医学皮肤病学领导者的努力的一部分。该公司已与Topper签订了雇佣协议，其中包括基本工资、绩效奖金和股权奖励。该公告是通过2024年4月10日的新闻稿发布的，并已在向美国证券交易委员会提交的8-K表格中进行了报道。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息